20/20 BioLabs, Inc. (Nasdaq: AIDX) reported its financial results for the third quarter ended September 30, 2026, and provided updates on its OneTest™ operations and business strategy. The company reported total revenue of $0.38 million for the third quarter of 2026, compared to $0.42 million in the prior year period. This decrease was attributed to the timing of state-funded firefighter cancer screening programs. For the first nine months of 2026, total revenue was $1.46 million, with OneTest™ revenue increasing 4.1% to $1.36 million.

Gross profit for the first nine months of 2026 was $0.46 million, with gross margin expanding to 31.7% from 31.5% in the prior year period. However, for the third quarter alone, gross profit was $0.10 million, resulting in a gross margin of 25.5%, down from 34.7% in the prior year period. This was described as reflecting lower testing volume and the impact of fixed laboratory costs.

Operating expenses for the third quarter were $1.49 million, compared to $0.95 million in the prior year period and $1.55 million in the second quarter of 2026. The year-over-year increase was primarily due to higher public company expenses. The company recorded a net loss of $1.38 million for the third quarter, compared to a net loss of $0.83 million in the prior year period and $1.51 million in the second quarter of 2026.

As of September 30, 2026, 20/20 BioLabs reported cash and cash equivalents of $3.63 million, a significant increase from $1.03 million at year-end 2025. This increase was primarily due to $6.0 million in Series E preferred financing completed during the first half of 2026. The company had no outstanding borrowings at quarter end.

On the operational front, the company noted that OneTest™ revenue represented 92.8% of total revenue for the first nine months of 2026. The company continued testing through Maryland's state-funded firefighter cancer screening program, with 18 groups of fire departments awarded more than $520,000 in grants. Additionally, Vermont executed a two-year contract specifying OneTest™ Premium for its statewide cancer screening program covering approximately 4,500 firefighters, with testing expected to begin contributing to revenue in Q4 2026.

Management announced plans to introduce a OneTest™ laboratory franchise model to expand distribution through regional laboratories under a royalty-based structure. The company also announced intentions to begin licensing its patented protein tumor marker testing technology to laboratories in the U.S. and internationally in 2027. As of the report date, more than 25,000 firefighters had been screened.